Selected research
Industry Growth & Trends
Global Attention Deficit Hyperactivity Disorder (ADHD) Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Attention Deficit Hyperactivity Disorder (ADHD) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Attention Deficit Hyperactivity Disorder (ADHD) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Attention Deficit Hyperactivity Disorder (ADHD) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Attention Deficit Hyperactivity Disorder (ADHD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Attention Deficit Hyperactivity Disorder (ADHD) market include Amneal Pharmaceuticals, Mallinckrodt, Neos Therapeutics, Noven Pharmaceuticals, Purdue Parma, Tris Pharma, CTFH, Eli Lilly and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Attention Deficit Hyperactivity Disorder (ADHD) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Attention Deficit Hyperactivity Disorder (ADHD) market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Attention Deficit Hyperactivity Disorder (ADHD) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Attention Deficit Hyperactivity Disorder (ADHD).
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Attention Deficit Hyperactivity Disorder (ADHD) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Attention Deficit Hyperactivity Disorder (ADHD) Market by Company
Amneal Pharmaceuticals
Mallinckrodt
Neos Therapeutics
Noven Pharmaceuticals
Purdue Parma
Tris Pharma
CTFH
Eli Lilly
Novartis
Johnson & Johnson
Takeda
Attention Deficit Hyperactivity Disorder (ADHD) Segment by Type
Stimulant
Non-stimulant
Attention Deficit Hyperactivity Disorder (ADHD) Segment by Application
Hospital Pharmacy
Retail Pharmacy
Attention Deficit Hyperactivity Disorder (ADHD) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attention Deficit Hyperactivity Disorder (ADHD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Attention Deficit Hyperactivity Disorder (ADHD) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attention Deficit Hyperactivity Disorder (ADHD).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Attention Deficit Hyperactivity Disorder (ADHD) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Stimulant
- Non-stimulant
Applications
- Hospital Pharmacy
- Retail Pharmacy
Companies covered
- Amneal Pharmaceuticals
- Mallinckrodt
- Neos Therapeutics
- Noven Pharmaceuticals
- Purdue Parma
- Tris Pharma
- CTFH
- Eli Lilly
- Novartis
- Johnson & Johnson
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Region (2021-2032)
- 1.4.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Region (2021-2026)
- 1.4.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Region (2027-2032)
- 1.5 Key Regions Attention Deficit Hyperactivity Disorder (ADHD) Market Size (2021-2032)
- 1.5.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth Rate (2021-2032)
- 1.5.4 South America Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth Rate (2021-2032)
2 Attention Deficit Hyperactivity Disorder (ADHD) Market by Type
- 2.1 Type Introduction
- 2.1.1 Stimulant
- 2.1.2 Non-stimulant
- 2.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type
- 2.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size Overview by Type (2021-2032)
- 2.2.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size Forecasted by Type (2027-2032)
- 2.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Regions
- 2.3.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Attention Deficit Hyperactivity Disorder (ADHD) Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Market Size Breakdown by Type (2021-2026)
3 Attention Deficit Hyperactivity Disorder (ADHD) Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital Pharmacy
- 3.1.2 Retail Pharmacy
- 3.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Application
- 3.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size Overview by Application (2021-2032)
- 3.2.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size Forecasted by Application (2027-2032)
- 3.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Regions
- 3.3.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Attention Deficit Hyperactivity Disorder (ADHD) Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Attention Deficit Hyperactivity Disorder (ADHD) Industry Trends
- 4.2 Attention Deficit Hyperactivity Disorder (ADHD) Industry Drivers
- 4.3 Attention Deficit Hyperactivity Disorder (ADHD) Industry Opportunities and Challenges
- 4.4 Attention Deficit Hyperactivity Disorder (ADHD) Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Attention Deficit Hyperactivity Disorder (ADHD) Revenue (2021-2026)
- 5.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Key Company Headquarters & Area Served
- 5.4 Global Attention Deficit Hyperactivity Disorder (ADHD) Company, Product Type & Application
- 5.5 Global Attention Deficit Hyperactivity Disorder (ADHD) Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Attention Deficit Hyperactivity Disorder (ADHD) Players Market Share by Revenue in 2025
- 5.6.3 2025 Attention Deficit Hyperactivity Disorder (ADHD) Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Amneal Pharmaceuticals
- 6.1.1 Amneal Pharmaceuticals Company Information
- 6.1.2 Amneal Pharmaceuticals Business Overview
- 6.1.3 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Product Portfolio
- 6.1.5 Amneal Pharmaceuticals Recent Developments
- 6.2 Mallinckrodt
- 6.2.1 Mallinckrodt Company Information
- 6.2.2 Mallinckrodt Business Overview
- 6.2.3 Mallinckrodt Attention Deficit Hyperactivity Disorder (ADHD) Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Mallinckrodt Attention Deficit Hyperactivity Disorder (ADHD) Product Portfolio
- 6.2.5 Mallinckrodt Recent Developments
- 6.3 Neos Therapeutics
- 6.3.1 Neos Therapeutics Company Information
- 6.3.2 Neos Therapeutics Business Overview
- 6.3.3 Neos Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Neos Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Product Portfolio
- 6.3.5 Neos Therapeutics Recent Developments
- 6.4 Noven Pharmaceuticals
- 6.4.1 Noven Pharmaceuticals Company Information
- 6.4.2 Noven Pharmaceuticals Business Overview
- 6.4.3 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Product Portfolio
- 6.4.5 Noven Pharmaceuticals Recent Developments
- 6.5 Purdue Parma
- 6.5.1 Purdue Parma Company Information
- 6.5.2 Purdue Parma Business Overview
- 6.5.3 Purdue Parma Attention Deficit Hyperactivity Disorder (ADHD) Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Purdue Parma Attention Deficit Hyperactivity Disorder (ADHD) Product Portfolio
- 6.5.5 Purdue Parma Recent Developments
- 6.6 Tris Pharma
- 6.6.1 Tris Pharma Company Information
- 6.6.2 Tris Pharma Business Overview
- 6.6.3 Tris Pharma Attention Deficit Hyperactivity Disorder (ADHD) Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Tris Pharma Attention Deficit Hyperactivity Disorder (ADHD) Product Portfolio
- 6.6.5 Tris Pharma Recent Developments
- 6.7 CTFH
- 6.7.1 CTFH Company Information
- 6.7.2 CTFH Business Overview
- 6.7.3 CTFH Attention Deficit Hyperactivity Disorder (ADHD) Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 CTFH Attention Deficit Hyperactivity Disorder (ADHD) Product Portfolio
- 6.7.5 CTFH Recent Developments
- 6.8 Eli Lilly
- 6.8.1 Eli Lilly Company Information
- 6.8.2 Eli Lilly Business Overview
- 6.8.3 Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Product Portfolio
- 6.8.5 Eli Lilly Recent Developments
- 6.9 Novartis
- 6.9.1 Novartis Company Information
- 6.9.2 Novartis Business Overview
- 6.9.3 Novartis Attention Deficit Hyperactivity Disorder (ADHD) Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Novartis Attention Deficit Hyperactivity Disorder (ADHD) Product Portfolio
- 6.9.5 Novartis Recent Developments
- 6.10 Johnson & Johnson
- 6.10.1 Johnson & Johnson Company Information
- 6.10.2 Johnson & Johnson Business Overview
- 6.10.3 Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Product Portfolio
- 6.10.5 Johnson & Johnson Recent Developments
- 6.11 Takeda
- 6.11.1 Takeda Company Information
- 6.11.2 Takeda Business Overview
- 6.11.3 Takeda Attention Deficit Hyperactivity Disorder (ADHD) Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Takeda Attention Deficit Hyperactivity Disorder (ADHD) Product Portfolio
- 6.11.5 Takeda Recent Developments
7 North America
- 7.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Country (2021-2026)
- 7.3 North America Attention Deficit Hyperactivity Disorder (ADHD) Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Country (2021-2026)
- 8.3 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Country (2021-2026)
- 10.3 South America Attention Deficit Hyperactivity Disorder (ADHD) Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst